SCHEMBL3018656

SCHEMBL3018656

Cc1cc(S(=O)(=O)C2CCN(c3nc(-c4ccc(Cl)cc4Cl)cs3)CC2)c(Cl)cc1Cl

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.54
NPSR1 Q6W5P4 2/20 0.42
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MAOA P21397 3/20 0.39
MAOB P27338 3/20 0.39
MAPT P10636 3/20 0.37
LMNA P02545 4/20 0.37
MAPK1 P28482 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
HPGD P15428 1/20 0.37
TSHR P16473 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3005795 0.90 AR (0.60) ARNPSR1RAB9ASMN1; SMN2MAOA
SCHEMBL3008651 0.89 AR (0.59) ARNPSR1RAB9ASMN1; SMN2MAOA
SCHEMBL2998403 0.89 SMN1; SMN2 (0.49) NPSR1RAB9ASMN1; SMN2MAPTLMNA
SCHEMBL3011287 0.88 SMN1; SMN2 (0.42) ARRAB9ASMN1; SMN2MAPTLMNA
SCHEMBL3016648 0.87 AR (0.57) ARNPSR1RAB9ASMN1; SMN2MAPT
SCHEMBL3017455 0.87 AR (0.55) ARNPSR1RAB9ASMN1; SMN2MAPT
SCHEMBL3008704 0.86 SMN1; SMN2 (0.45) ARNPSR1RAB9ASMN1; SMN2MAPT
SCHEMBL3012829 0.86 AR (0.52) ARNPSR1RAB9ASMN1; SMN2MAOA
SCHEMBL2999680 0.86 SMN1; SMN2 (0.39) ARRAB9ASMN1; SMN2MAPTLMNA
SCHEMBL3012448 0.86 AR (0.55) ARNPSR1RAB9ASMN1; SMN2MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885NPSR1 764/4885RAB9A 2943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.